These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23901346)

  • 1. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.
    Rawal S; Young D; Williams M; Colombo M; Krishnappa R; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
    J Cancer; 2013; 4(6):468-72. PubMed ID: 23901346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.
    Kelly GM; Kong YH; Dobi A; Srivastava S; Sesterhenn IA; Pathmanathan R; Tan HM; Tan SH; Cheong SC
    Mol Clin Oncol; 2015 Jan; 3(1):23-30. PubMed ID: 25469265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.
    Rosen P; Pfister D; Young D; Petrovics G; Chen Y; Cullen J; Böhm D; Perner S; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S
    Urology; 2012 Oct; 80(4):749-53. PubMed ID: 22950997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
    Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
    Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.
    Furusato B; Tan SH; Young D; Dobi A; Sun C; Mohamed AA; Thangapazham R; Chen Y; McMaster G; Sreenath T; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):228-37. PubMed ID: 20585344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
    Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
    J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization.
    Zhang S; Pavlovitz B; Tull J; Wang Y; Deng FM; Fuller C
    Diagn Mol Pathol; 2010 Sep; 19(3):151-6. PubMed ID: 20736744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
    Sreenath TL; Dobi A; Petrovics G; Srivastava S
    J Carcinog; 2011; 10():37. PubMed ID: 22279422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors.
    Dubovenko A; Serebryiskaya T; Nikolsky Y; Nikolskaya T; Perlina A; JeBailey L; Bureeva S; Katta S; Srivastava S; Dobi A; Khasanova T
    J Cancer; 2015; 6(6):490-501. PubMed ID: 26000039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene Fusion.
    Burdova A; Rulisek P; Bouchal J; Král M; Student V; Kolar Z
    Klin Onkol; 2018; 31(6):421-428. PubMed ID: 30545222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predominance of ERG-negative high-grade prostate cancers in African American men.
    Farrell J; Young D; Chen Y; Cullen J; Rosner IL; Kagan J; Srivastava S; McLEOD DG; Sesterhenn IA; Srivastava S; Petrovics G
    Mol Clin Oncol; 2014 Nov; 2(6):982-986. PubMed ID: 25279185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
    Shah RB
    Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men.
    Baohong J; Sedarsky J; Srivastava S; Sesterhenn I; Dobi A; Quanlin L
    J Cancer; 2019; 10(9):1991-1996. PubMed ID: 31205559
    [No Abstract]   [Full Text] [Related]  

  • 18. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and clinical application of
    Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
    Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.